The guidelines acknowledge that data continues to build for IgA anti-B2GPI, but currently testing for this isotype is recommended in patients with negative IgG and IgM anti-B2GPI and in whom APS is still suspected. This evidence concerns the gene CD79A and autoimmune polyendocrinopathy.